Next Generation Sequencing in Non-Small Cell Lung Cancer: Pitfalls and Opportunities

Lung cancer remains the first cause of cancer-related deaths worldwide. Thanks to the improvement in the knowledge of the biology of non-small cell lung cancer (NSCLC), patients’ survival has significantly improved. A growing number of targetable molecular alterations have been identified. Next-gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazzari, Chiara, Bulotta, Alessandra, Cangi, Maria Giulia, Bucci, Gabriele, Pecciarini, Lorenza, Bonfiglio, Silvia, Lorusso, Vincenza, Ippati, Stefania, Arrigoni, Gianluigi, Grassini, Greta, Doglioni, Claudio, Gregorc, Vanesa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765222/
https://www.ncbi.nlm.nih.gov/pubmed/33333743
http://dx.doi.org/10.3390/diagnostics10121092
Descripción
Sumario:Lung cancer remains the first cause of cancer-related deaths worldwide. Thanks to the improvement in the knowledge of the biology of non-small cell lung cancer (NSCLC), patients’ survival has significantly improved. A growing number of targetable molecular alterations have been identified. Next-generation sequencing (NGS) has become one of the methodologies entered in clinical practice and was recently recommended by the European society for medical oncology (ESMO) to perform a comprehensive molecular characterization in patients with cancer. The current review provides an overview of the clinical trials that have explored the impact of NGS in patients with cancer, its limits, and advantages.

Ejemplares similares